Michael Fedkenheuer

Michael Fedkenheuer

Auto-generated profile, based on publicly available information

Michael Fedkenheuer

Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Nature
Verified
Journal Article
Closed access
PDF file
RSrobin sebastian
robin sebastian
ESEric G. Sun
Eric G. Sun
MFMichael Fedkenheuer
Michael Fedkenheuer
HFHaiqing Fu
Haiqing Fu
SJSeolKyoung Jung
SeolKyoung Jung
MAMirit Aladjem
Mirit Aladjem

20 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MFMichael Fedkenheuer
Michael Fedkenheuer
YSYafang Shang
Yafang Shang
SJSeolkyoung Jung
Seolkyoung Jung
KFKevin Fedkenheuer
Kevin Fedkenheuer
SPSolji Park
Solji Park
RCRafael Casellas
Rafael Casellas
Cells undergo tens of thousands of DNA-damaging events each day. Defects in repairing double-stranded breaks (DSBs) can lead to genomic instability, contributing to cancer, genetic disorders, immunological diseases, and developmental defects. Cohesin, a multi-subunit protein complex, plays a crucial role in both chromosome organization and DNA repair by creating architectural loops through chromatin extrusion. However, the mechanisms by which cohesin regulates these distinct processes are not fully understood. In this study, we identify two separate roles for cohesin in DNA repair within mammalian cells. First, cohesin serves as an intrinsic architectural factor that normally prevents interactions between damaged chromatin. Second, cohesin has an architecture-independent role triggered by ATM phosphorylation of SMC1, which enhances the efficiency of repair. Our findings suggest that these two functions work together to reduce the occurrence of translocations and deletions associated with non-homologous end joining, thereby maintaining genomic stability.

13 May 2022 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
DHDavid O. Holland
David O. Holland
VGValer Gotea
Valer Gotea
KFKevin Fedkenheuer
Kevin Fedkenheuer
SJSushil Kumar Jaiswal
Sushil Kumar Jaiswal
CBCatherine Baugher
Catherine Baugher
LELaura Elnitski
Laura Elnitski
Mutations to the human kinome are known to play causal roles in cancer. The kinome regulates numerous cell processes including growth, proliferation, differentiation, and apoptosis. In addition to aberrant expression, aberrant alternative splicing of cancer-driver genes is receiving increased attention as it could lead to loss or gain of functional domains, altering a kinase’s downstream impact. The present study quantifies changes in gene expression and isoform ratios in the kinome of metastatic melanoma cells relative to primary tumors. We contrast 538 total kinases and 3,040 known kinase isoforms between 103 primary tumor and 367 metastatic samples from The Cancer Genome Atlas (TCGA). We find strong evidence of differential expression (DE) at the gene level in 123 kinases (23%). Additionally, of the 468 kinases with alternative isoforms, 60 (13%) had significant difference in isoform ratios (DIR). Notably, DE and DIR have little correlation; for instance, although DE highlights enrichment in receptor tyrosine kinases (RTKs), DIR identifies altered splicing in non-receptor tyrosine kinases (nRTKs). Using exon junction mapping, we identify five examples of splicing events favored in metastatic samples. We demonstrate differential apoptosis and protein localization between SLK isoforms in metastatic melanoma. We cluster isoform expression data and identify subgroups that correlate with genomic subtypes and anatomic tumor locations. Notably, distinct DE and DIR patterns separate samples with BRAF hotspot mutations and (N/K/H)RAS hotspot mutations, the latter of which lacks effective kinase inhibitor treatments. DE in RAS mutants concentrates in CMGC kinases (a group including cell cycle and splicing regulators) rather than RTKs as in BRAF mutants. Furthermore, isoforms in the RAS kinase subgroup show enrichment for cancer-related processes such as angiogenesis and cell migration. Our results reveal a new approach to therapeutic target identification and demonstrate how different mutational subtypes may respond differently to treatments highlighting possible new driver events in cancer.

22 July 2024 in Cancer Letters
Verified
Journal Article
Open access
SJSushil Kumar Jaiswal
Sushil Kumar Jaiswal
KFKevin Fedkenheuer
Kevin Fedkenheuer
RKRonak Khamar
Ronak Khamar
HTHua Tan
Hua Tan
VGValer Gotea
Valer Gotea
LELaura Elnitski
Laura Elnitski